Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
Health Canada’s Directorate has issued a non-compliance notice to Dr. Reddy’s Laboratories regarding its generic semaglutide for weight loss, raising questions over the company’s regulatory pathway in North America. The notice cited failures to meet certain submission or compliance conditions linked to manufacturing or data requirements for approval. Semaglutide remains one of the most tightly scrutinised drug categories globally, given its soaring demand and high public-health impact. While the notice does not constitute a rejection, Dr. Reddy’s must address the compliance gaps before its application can progress. The development comes at a time when multiple global manufacturers are preparing to launch semaglutide generics once key patents expire. Industry observers view the notice as a sign that regulators will enforce stricter oversight on GLP-1 generics, especially in markets where safety, purity and bioequivalence standards face exceptional scrutiny.
You May Interested In
2026-07-26
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA Slams Door on Chinese Food Exports: Inspection Refusals Trigger Automatic Detentions
-
The End of Hype: Europe’s Bio-stimulant Industry Faces a Science-First Reckoning by 2030
-
Japan Tightens the Rules—Then Loosens Them: A Surprising Shift in Food Additive Policy
-
Four Fine Chemical Units of Huajin Aramco Project – HDPE, EO/EG, etc. – Reach Mechanical Completion
-
关于将二氟乙咪酯等16种物质列入《非药用类麻醉药品和精神药品目录》的公告 Announcement on the Inclusion of 16 Substances including Difluoroetomidate in the Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
EU Biocidal Data Protection Extension Raises the Stakes for Chemical Market Entry
-
Sudden Turmoil in Middle East Shipping Routes: Multiple Carriers Announce Emergency Navigation and Surcharge Policies
-
Your Plant Has the Data. Your AI Cannot Reach It. Here Is Why That Is the Core Problem in Chemical Manufacturing.
-
FDA Dye Pledges Push Natural Colors Into the Mainstream
Recommend Reading
-
FDA Tightens the Solvent Side of Natural Color Production
-
FDA Reopens BHA Review—Why One Preservative Is Becoming a Global Wake-Up Call for Food Additives
-
“No Artificial Colors” Gets Redefined—Why FDA’s Labeling Shift Is Roiling the Food Additive World
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
G20 Pushes Fertilizer Access as Food-Security Risk Rises
-
In September, the price center of ethylene glycol shifted downward; in October, there's a high probability of a weak start followed by a strong performance
-
September Ethyl Acetate Price Trends Fluctuate and Consolidate
-
Support Effective, January Normal Butanol Market Price Increase Exceeds 18% in China
-
Premium Global Chemical Sourcing Requests (31 Jan - 4 Feb, 2026)
-
What is a Surfactant? (Definition, Types, and How They Work)